Literature DB >> 20051329

Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres.

S J Doe1, A McSorley, B Isalska, A M Kearns, R Bright-Thomas, A L Brennan, A K Webb, A M Jones.   

Abstract

BACKGROUND: The prevalence of MRSA in patients with CF has risen in recent years. We adhere to a policy of segregation and barrier nursing to manage patients with MRSA, and we actively pursue eradication of MRSA. We have evaluated our experiences of MRSA infection in our large adult CF centre.
METHOD: A retrospective review of all MRSA-positive patients from 1998 to 2008 was undertaken. Isolates were subjected to molecular identification to elucidate possible patient-to-patient transmission events. Eradication attempts were scrutinised.
RESULTS: We have maintained a low incidence and prevalence (below 3%) of MRSA within this large cohort. A total of 15 pulsotypes of MRSA were identified among the 24 isolates examined, epidemiological data suggested no patient-patient transmission. Based on 6 month follow-up data, successful eradication was achieved in 81% patients. This includes those who had harboured infection for some time. Twenty-one (80.8%) required only one course of treatment, 3 (11.6%) patients required two different regimes and 2 (7.5%) required three courses to fully eradicate the organism.
CONCLUSION: Strict infection control procedures can control MRSA infection and keep the prevalence low in CF clinics. Eradication is achievable in the majority of patients even when significant time has lapsed from initial isolation. In some instances, up to 3 courses of antibiotics were required to achieve eradication. Copyright (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051329     DOI: 10.1016/j.jcf.2009.11.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  7 in total

1.  Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial.

Authors:  Marianne Sponer Muhlebach; Valeria Beckett; Elena Popowitch; Melissa B Miller; Arthur Baines; Nicole Mayer-Hamblett; Edith T Zemanick; Wynton C Hoover; Jill M VanDalfsen; Preston Campbell; Christopher H Goss
Journal:  Thorax       Date:  2016-11-15       Impact factor: 9.139

Review 2.  Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Authors:  James F Chmiel; Timothy R Aksamit; Sanjay H Chotirmall; Elliott C Dasenbrook; J Stuart Elborn; John J LiPuma; Sarath C Ranganathan; Valerie J Waters; Felix A Ratjen
Journal:  Ann Am Thorac Soc       Date:  2014-09

3.  Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.

Authors:  Josephine M Bryant; Dorothy M Grogono; Daniela Rodriguez-Rincon; Isobel Everall; Karen P Brown; Pablo Moreno; Deepshikha Verma; Emily Hill; Judith Drijkoningen; Peter Gilligan; Charles R Esther; Peadar G Noone; Olivia Giddings; Scott C Bell; Rachel Thomson; Claire E Wainwright; Chris Coulter; Sushil Pandey; Michelle E Wood; Rebecca E Stockwell; Kay A Ramsay; Laura J Sherrard; Timothy J Kidd; Nassib Jabbour; Graham R Johnson; Luke D Knibbs; Lidia Morawska; Peter D Sly; Andrew Jones; Diana Bilton; Ian Laurenson; Michael Ruddy; Stephen Bourke; Ian Cjw Bowler; Stephen J Chapman; Andrew Clayton; Mairi Cullen; Thomas Daniels; Owen Dempsey; Miles Denton; Maya Desai; Richard J Drew; Frank Edenborough; Jason Evans; Jonathan Folb; Helen Humphrey; Barbara Isalska; Søren Jensen-Fangel; Bodil Jönsson; Andrew M Jones; Terese L Katzenstein; Troels Lillebaek; Gordon MacGregor; Sarah Mayell; Michael Millar; Deborah Modha; Edward F Nash; Christopher O'Brien; Deirdre O'Brien; Chandra Ohri; Caroline S Pao; Daniel Peckham; Felicity Perrin; Audrey Perry; Tania Pressler; Laura Prtak; Tavs Qvist; Ali Robb; Helen Rodgers; Kirsten Schaffer; Nadia Shafi; Jakko van Ingen; Martin Walshaw; Danie Watson; Noreen West; Joanna Whitehouse; Charles S Haworth; Simon R Harris; Diane Ordway; Julian Parkhill; R Andres Floto
Journal:  Science       Date:  2016-11-11       Impact factor: 47.728

4.  Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis--the PMEP trial: study protocol for a randomized controlled trial.

Authors:  Mark T Jennings; Michael P Boyle; David Weaver; Karen A Callahan; Elliott C Dasenbrook
Journal:  Trials       Date:  2014-06-12       Impact factor: 2.279

5.  MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis.

Authors:  Emilie Vallières; Jacqueline C Rendall; John E Moore; John McCaughan; Anne I Hoeritzauer; Michael M Tunney; Joseph Stuart Elborn; Damian G Downey
Journal:  ERJ Open Res       Date:  2016-03-15

Review 6.  Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

Authors:  David Kh Lo; Marianne S Muhlebach; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2018-07-21

Review 7.  Update on key emerging challenges in cystic fibrosis.

Authors:  Mark T Jennings; Kristin A Riekert; Michael P Boyle
Journal:  Med Princ Pract       Date:  2014-01-10       Impact factor: 1.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.